Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Meibomian Gland Dysfunction × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Breast Neoplasms 8974 Neoplasms 6886 Carcinoma, Non-Small-Cell Lung 5046 Prostatic Neoplasms 4451 Colorectal Neoplasms 4031 Lung Neoplasms 3263 Leukemia, Myeloid, Acute 2718 Neoplasm Metastasis 2709 Multiple Myeloma 2700 Pancreatic Neoplasms 2516 Melanoma 2342 Lymphoma 2288 Ovarian Neoplasms 2267 Carcinoma, Hepatocellular 2180 Stomach Neoplasms 2063 Recurrence 1950 Head and Neck Neoplasms 1837 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1824 Lymphoma, Non-Hodgkin 1810 Leukemia 1800 Brain Neoplasms 1709 Glioblastoma 1603 Colonic Neoplasms 1573 Leukemia, Lymphocytic, Chronic, B-Cell 1546 Rectal Neoplasms 1513 Uterine Cervical Neoplasms 1463 Lymphoma, Follicular 1436 Squamous Cell Carcinoma of Head and Neck 1432 Lymphoma, Large B-Cell, Diffuse 1400 Carcinoma, Renal Cell 1376

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01763437 2017-01-12

TET

The Cleveland Clinic

Phase EARLY_PHASE1 Withdrawn

Meibomian Gland Dysfunction, Rosacea, Chalazion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡